Clinical Trials Sponsored by Zhonglin Hao

Total 4223 results

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers

Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Platinum-resistant Ovarian Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

Acromegaly

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.

SARS-CoV-2

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment

Renal Impairment

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate Relative Bioavailability and Food-Effect of HA121-28 Tablet B in Healthy Subjects

Healthy Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Mass Balance and Biotransformation Study of [14C]DBPR108 in Human

Healthy Male Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor

Advanced Solid Tumor

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Investigate the Drug-drug Interactions (DDIs) Between SKLB1028 and Midazolam in Healthy Subjects

Healthy Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects

Healthy Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM

Type 2 Diabetes Mellitus

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers

Asthma; Allergic Rhinitis

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study of CSPCHA131 in Patients With Advanced Solid Tumor

Advanced Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Bioequivalence

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran

Peripheral Artery Disease

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subject

Depression
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects

Depression

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

The Safety and Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers

Lower Extremity Arterial Occlusive Diseases

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Withdrawn

Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

Gastric Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Locally Advanced Unresectable Esophageal Squamous Carcinoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer

Head and Neck Cancer | Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

HER2-positive Advanced Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

HER2-positive Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)

Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer

Pancreatic Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors

Advanced Solid Tumor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)

Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies

Lymphoma | Acute Myeloid Leukemia | Multiple Myeloma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of SYHA1805 in Healthy Subjects

Healthy Subjects
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer

Uterine Cervical Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Study of DP303c Injection in Patients With Advanced Ovarian Cancer

Ovarian Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)

Medullary Thyroid Carcinoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated (ALIVE)

Acute Myeloid Leukemia (AML)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC

Advanced Hepatocellular Carcinoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain

Pain

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors

Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.

SARS-CoV-2

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Effect of Different Meal Types on the Pharmacokinetics of DBPR108 in Healthy Subjects

Healthy Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer

Biliary Tract Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Suspended

A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor

Advanced Malignant Tumor

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male Subjects

Healthy Male Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China

Clinical Trials Sponsored by Zhonglin Hao

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations